Cargando…

Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People

BACKGROUND: The elderly people generally have poor tolerance to drugs and an increased risk of adverse effects. Our study was designed to determine the effect and safety of Helicobacter pylori (H. pylori) eradication treatment based on molecular pathologic antibiotic resistance in Chinese elderly pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Chun, Fan, Yan-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234187/
https://www.ncbi.nlm.nih.gov/pubmed/35769552
http://dx.doi.org/10.2147/IDR.S371113
_version_ 1784736006552944640
author Gao, Chun
Fan, Yan-Hua
author_facet Gao, Chun
Fan, Yan-Hua
author_sort Gao, Chun
collection PubMed
description BACKGROUND: The elderly people generally have poor tolerance to drugs and an increased risk of adverse effects. Our study was designed to determine the effect and safety of Helicobacter pylori (H. pylori) eradication treatment based on molecular pathologic antibiotic resistance in Chinese elderly people over the age of 60 years. METHODS: A total of 364 people were retrospectively analyzed, including 113 older people over 60 and 251 young and middle-aged people in the age of 20–59 years. Real-time PCR detection and conventional PCR and sequencing method were used for drug susceptibility testing. As the main outcome measure, the eradication rates (ERs) with their 95% confidence intervals (CIs) were analyzed by intention to treat (ITT) and per protocol (PP). For the safety of therapy, adverse events were analyzed. RESULTS: For the total people, the resistance rates to clarithromycin (CLR), amoxicillin (AMX), fluoroquinolone (FLQ) and tetracycline (TET) were 65.06%, 7.54%, 61.39% and 20.37%, respectively. After they were divided into two groups, the resistance rates were 62.39% (CLR), 9.09% (AMX), 69.64% (FLQ) and 22.45% (TET) in the 113 older people over 60, and 66.26%, 6.85%, 57.66% and 19.47% in the 251 young and middle-aged people in 20–59. By the ITT analysis, the ERs were 92.04% (95% CI, 86.97–97.10%, n=113) in the older people and 92.43% (95% CI, 89.14–95.73%, n=251) in the young and middle-aged people. By the PP analysis, the ERs were 96.30% (95% CI, 92.68–99.92%, n=108) and 94.69% (95% CI, 91.87–97.52%, n=245), respectively. No significant differences were shown both in the ITT analysis (P=0.896) and in the PP analysis (P=0.517). The three most common adverse events were black stool, dysgeusia and diarrhea, and no serious adverse event was reported. CONCLUSION: H. pylori eradication treatment based on molecular pathologic antibiotic resistance showed good effect and safety in Chinese elderly people.
format Online
Article
Text
id pubmed-9234187
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92341872022-06-28 Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People Gao, Chun Fan, Yan-Hua Infect Drug Resist Original Research BACKGROUND: The elderly people generally have poor tolerance to drugs and an increased risk of adverse effects. Our study was designed to determine the effect and safety of Helicobacter pylori (H. pylori) eradication treatment based on molecular pathologic antibiotic resistance in Chinese elderly people over the age of 60 years. METHODS: A total of 364 people were retrospectively analyzed, including 113 older people over 60 and 251 young and middle-aged people in the age of 20–59 years. Real-time PCR detection and conventional PCR and sequencing method were used for drug susceptibility testing. As the main outcome measure, the eradication rates (ERs) with their 95% confidence intervals (CIs) were analyzed by intention to treat (ITT) and per protocol (PP). For the safety of therapy, adverse events were analyzed. RESULTS: For the total people, the resistance rates to clarithromycin (CLR), amoxicillin (AMX), fluoroquinolone (FLQ) and tetracycline (TET) were 65.06%, 7.54%, 61.39% and 20.37%, respectively. After they were divided into two groups, the resistance rates were 62.39% (CLR), 9.09% (AMX), 69.64% (FLQ) and 22.45% (TET) in the 113 older people over 60, and 66.26%, 6.85%, 57.66% and 19.47% in the 251 young and middle-aged people in 20–59. By the ITT analysis, the ERs were 92.04% (95% CI, 86.97–97.10%, n=113) in the older people and 92.43% (95% CI, 89.14–95.73%, n=251) in the young and middle-aged people. By the PP analysis, the ERs were 96.30% (95% CI, 92.68–99.92%, n=108) and 94.69% (95% CI, 91.87–97.52%, n=245), respectively. No significant differences were shown both in the ITT analysis (P=0.896) and in the PP analysis (P=0.517). The three most common adverse events were black stool, dysgeusia and diarrhea, and no serious adverse event was reported. CONCLUSION: H. pylori eradication treatment based on molecular pathologic antibiotic resistance showed good effect and safety in Chinese elderly people. Dove 2022-06-22 /pmc/articles/PMC9234187/ /pubmed/35769552 http://dx.doi.org/10.2147/IDR.S371113 Text en © 2022 Gao and Fan. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gao, Chun
Fan, Yan-Hua
Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People
title Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People
title_full Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People
title_fullStr Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People
title_full_unstemmed Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People
title_short Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People
title_sort effect and safety of helicobacter pylori eradication treatment based on molecular pathologic antibiotic resistance in chinese elderly people
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234187/
https://www.ncbi.nlm.nih.gov/pubmed/35769552
http://dx.doi.org/10.2147/IDR.S371113
work_keys_str_mv AT gaochun effectandsafetyofhelicobacterpylorieradicationtreatmentbasedonmolecularpathologicantibioticresistanceinchineseelderlypeople
AT fanyanhua effectandsafetyofhelicobacterpylorieradicationtreatmentbasedonmolecularpathologicantibioticresistanceinchineseelderlypeople